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The observation by Dr. Wheatcroft and colleagues of life-
threatening coronary artery spasm following sirolimus-eluting
stent deployment is impressive and underscores the important role
of vasomotor function after stent implantation. A recent report
demonstrated severe multivessel spasms and aborted sudden car-
diac death 10 h after paclitaxel-eluting stent implantation (2). A
similar phenomenon has been described after high-dose intracoro-
nary beta-radiation by Scheinert et al. (3), who concluded that
vasoconstriction is a frequent finding a few minutes after beta-
radiation and may be due to acute radiation-induced endothelial
dysfunction.
These two letters underline the key role of re-endothelialization
for maintaining a normal vascular function after stent implantation
or intracoronary radiotherapy.
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Preventing Type 2 Diabetes
Mellitus With Angiotensin
Blockade: Is it Clinically Relevant?
Diabetes mellitus is a serious, costly, and increasingly common
disease. In light of the dramatic epidemic of type 2 diabetes and its
adverse prognostic implications, strategies to prevent or delay this
major health problem are of paramount importance.
Abuissa et al. (1), in a meta-analysis of 12 recent randomized
controlled clinical trials that enrolled patients with hypertension,
chronic heart failure, or coronary heart disease, showed that
angiotensin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARBs) produced a highly significant 25%
reduction (95% confidence interval [CI], 18% to 31%) in the
incidence of new-onset diabetes when compared to placebo,
diuretics, beta-blockers, or calcium channel antagonists. Apart
from some limitations (e.g., new-onset diabetes as secondary end
point or as post hoc analysis; open-blinded end point design in
some trials; higher proportion of patients receiving drugs that
increase insulin resistance such as diuretics and beta-blockers in
the comparator groups; and absence of standardization for serial
testing of blood glucose levels), the investigators concluded that
the use of an ACE inhibitor or ARB should be considered in
patients with prediabetic conditions such as metabolic syndrome,
hypertension, impaired fasting glucose, family history of diabetes,
obesity, congestive heart failure, or coronary heart disease.
However, focusing solely on the relative risk (RR) reduction and
utilizing a surrogate marker (prevention of a fasting plasma glucose
126 mg/dl at two different visits in patients with no diabetes at
the time of presentation) make it difficult to estimate the real
benefit of the proposed intervention.
On the basis of the Abuissa et al. (1) meta-analysis, despite a
significant RR reduction of 25%, the absolute risk difference between
an ACE inhibitor or an ARB and the other agents was only 3.1 cases
per 1,000 patient-years (decreasing from 17.4 to 14.3 per 1,000
patient-years), which means that 323 patients (1/0.0031) must be
treated for one year to prevent the new onset of one case of diabetes
mellitus. Moreover, it is important to mention that the final goal of
the inhibition of the renin-angiotensin-aldosterone system in this
particular situation is to prevent the diabetes-related morbidity and
mortality rather than merely the diagnosis of diabetes. If one assumes
that the risk of any diabetes-related macrovascular or microvascular
complication is about 46 per 1,000 patient-years for newly diagnosed
patients with type 2 diabetes (2), the number needed to treat (NNT)
per year in order to prevent not only the development of type 2
diabetes mellitus but also any one of its subsequent complications
increases to 7,013 [(1/0.0031) (1/0.046)]. Even with a longer-term
follow-up, let us say 10 years, given the time frame from onset of
diabetes to diabetes-related complications, the NNT to prevent a
clinical event would be extraordinarily high.
Needless to say, this type of analysis does not contemplate the
already proved beneficial effects of ACE inhibitors and ARBs (by
other mechanisms) on the reduction of major vascular events in
certain conditions such as heart failure or after myocardial infarc-
tion. Of note, in another recent meta-analysis (3), ACE inhibitors
or ARBs decreased patients’ odds of developing new-onset type 2
diabetes but did not reduce the odds of mortality, cardiovascular,
or cerebrovascular outcomes among patients with hypertension.
Therefore, instead of searching for pharmacological therapies that
are statistically attractive but will never be clinically relevant or
cost-effective, prevention of diabetes mellitus should be fundamen-
tally approached by reducing the patient’s weight and increasing
his or her physical activity (4,5).
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REPLY
We appreciate the interest by Dr. Rassi in our recent study on the
role of angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) in diabetes prevention (1).
We agree that lifestyle modifications that increase physical activity
and minimize abdominal obesity are the most rational and cost-
effective strategies for preventing type 2 diabetes. Despite this
knowledge, compliance with a prescription for daily exercise and
lasting weight loss proves difficult for many people; the epidemic of
diabetes continues to escalate. Thus, safe pharmacologic ap-
proaches for preventing this disease will probably be relevant and
important for many individuals.
Screening for new-onset diabetes using the American Diabetes
Association criteria of a fasting plasma glucose of 126 mg/dl at
two different visits in patients with no diabetes at the time of
enrollment is a valid initial test to identify this disease at its early
stages and prevent its chronic sequelae. However, the use of data
from relatively short-term studies to calculate a number-needed-
to-treat (NNT) can be misleading, as the risk of diabetes accrues
over decades or, indeed, a lifetime.
Insulin resistance is a common pathophysiologic disturbance
that plays a causal role in both hypertension and type 2 diabetes. It
also results in overactivity of the rennin-angiotensin-aldosterone
system leading to hypertrophy and stiffening of smooth muscles in
the arterial wall and left ventricle. Angiotensin-converting enzyme
inhibitors and ARBs have a proven efficacy for improving outcomes
in insulin-resistant conditions, such as hypertension, coronary heart
disease (CHD), and congestive heart failure, and they are the most
effective antihypertensive agents for regressing smooth muscle hyper-
trophy commonly seen in these conditions (2). The fact that they also
reduce the risk of new-onset diabetes is just one more reason to choose
them for these established indications over other antihypertensive
agents that worsen insulin sensitivity, such as traditional beta-blockers
and diuretics (3).
Metabolic syndrome is a more robust marker for risk of type 2
diabetes and CHD events (4). If the NNT with an ACE inhibitor
or ARB to prevent the development of new-onset diabetes in these
patients is to be calculated, it will be substantially lower than that
found in populations from our study, who were obviously at a
lower risk. Therefore, as we have advocated, targeting high-risk
prediabetic individuals for use of an ACE inhibitor or ARB
therapy will increase the cost-effectiveness of these medications.
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Long-Term Bosentan
Treatment in Children With
Pulmonary Arterial Hypertension
One of the core principles of scientific research is to provide full
details of the experimental methods for replication in further study
or clinical practice. As with many published studies (1), Rosenz-
weig et al. (2) failed to provide details of the drug formulation in
their report. Bosentan is currently only commercially available in
tablet form, and the dosing used in their study appears to be
multiples of halved/quartered tablets. It is widely recognized that
splitting tablets causes significant dosing inaccuracy, even when
commercially available tablet cutters are used (3,4). Furthermore,
many children are unable to swallow whole tablets (5), and
crushing the tablets can impair drug absorption (6). Rosenzweig
et al. (2) do not report how their patients took the dose (whether
or not it was swallowed whole).
If the published report does not detail the drug formulation and
method of administration, the reliability of any findings is ques-
tionable as the methods cannot be repeated accurately. If tablets
were cut in half/quartered and crushed, both the amount of drug
administered and its absorption are questionable, bringing the
validity of the results into doubt.
In their report, Rosenzweig et al. (2) cite a pharmacokinetic
study (7) on the dosing of bosentan in pediatric patients that also
fails to give formulation and administration details and whose
lowest dose is 31.25 mg as opposed to 15.6 mg in Rosenzweig et al.
(2). Bosentan may well be a useful agent in the treatment of
pulmonary arterial hypertension in children; surely it is now time
that a pediatric liquid formulation be developed, the efficacy and
dose optimization of which can be addressed in a well-conducted
prospective clinical trial.
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